{"anticipatedPostingDate":"2028-03","denomUnitsSelected":"Participants","description":"Incidence of treatment emergent adverse events including grade ≥ 3 treatment emergent adverse events, serious treatment emergent adverse events, treatment emergent adverse events leading to treatment discontinuation, fatal treatment emergent adverse events, and treatment-related treatment emergent adverse events.","reportingStatus":"NOT_POSTED","timeFrame":"Up to approximately 4 years","title":"Number of Participants With Anti-tarlatamab Antibodies","type":"SECONDARY"}